Levetiracetam controlled release - Sun Pharma Advanced Research Company

Drug Profile

Levetiracetam controlled release - Sun Pharma Advanced Research Company

Alternative Names: Elepsia XR; Levetiracetam ER - Sun Pharma Advanced Research Company; Levetiracetam extended release - Sun Pharma Advanced Research Company

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Epilepsy

Most Recent Events

  • 10 Jan 2018 Levetiracetam controlled release is still not refiled for regulatory approval for Epilepsy in USA (literature review)
  • 30 Oct 2017 Levetiracetam controlled release is being considered for re-filing for regulatory approval in USA (PO) (SPARC pipeline, August 2017)
  • 21 Apr 2017 Pooled pharmacokinetics and safety data from a bioequivalence trials in Epilepsy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top